Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marlise Rachael Luskin, M.D.

Co-Author

This page shows the publications co-authored by Marlise Luskin and Donna Neuberg.
Connection Strength

0.410
  1. Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. Am J Hematol. 2021 07 01; 96(7):E259-E262.
    View in: PubMed
    Score: 0.233
  2. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 Mar 15; 1-8.
    View in: PubMed
    Score: 0.062
  3. Prediction of Life-threatening and Disabling Bleeding in Patients with AML Receiving Intensive Induction Chemotherapy. Blood Adv. 2022 Jan 26.
    View in: PubMed
    Score: 0.061
  4. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.053
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.